How does GLP-1 work? Not the way most people assume. They don’t melt fat off your body or let you skip the rules of weight loss.
What they actually do is more ordinary than the hype suggests: weight change follows energy balance, the gap between the energy you take in and the energy you spend, and these drugs act almost entirely on the energy-in side.
The chain is short. The medication lowers your appetite, so you eat less, so fewer calories come in than your body burns. That steady shortfall is what moves the scale.
Every link in that chain has been measured, including the point where it stalls.
What Energy Balance Actually Means
Most of the energy you burn has nothing to do with exercise. Energy balance is a simple equation with two sides. Energy in is the calories (kilojoules) you take from food and drink.
Energy out is everything your body spends. The largest share by far is your basal metabolic rate, the energy it takes just to keep you alive at rest. Physical activity adds more, and a smaller slice goes to digesting the food itself.
When energy in stays below energy out for long enough, your body makes up the difference by drawing on stored fat. That gap is a calorie deficit, and a sustained deficit is the one thing that produces fat loss, whether it comes from eating less, moving more, surgery, or a medication. The source doesn’t change the result, because your body can’t tell whether the shortfall came from a smaller plate or a weekly injection. Nothing gets around it.
Calories and kilojoules measure the same energy in different units. One calorie is about 4.2 kilojoules, so a 500-calorie daily deficit is about 2,100 kilojoules, and a 100-calorie snack reads about 420 kilojoules.
You don’t need to track the math of your own metabolism to follow the logic. The direction is the point: a GLP-1 medication makes its main move on the energy-in side.
How Does GLP-1 Work? They Turn Down Calories In
A drug you inject once a week ends up changing how much you want to eat, and it does that by imitating a hormone you already make. GLP-1, or glucagon-like peptide-1, is released by your gut after a meal to signal that you’ve had enough.
The medications are long-acting copies of that hormone, so the “I’ve eaten enough” message stays switched on far longer than your own version manages. Semaglutide is close enough to the natural hormone, about 94% identical, that your appetite system responds to it as the real thing.
That plays out in two ways. Semaglutide crosses the blood-brain barrier and reaches appetite-control regions, mainly the hypothalamus and an area of the brainstem called the area postrema, where it turns down hunger and the pull toward food. It also slows how quickly your stomach empties, so a meal keeps you satisfied for longer.
Both effects push in the same direction: you eat less without gritting your teeth to do it. Reduced hunger plus slower digestion is what people mean by GLP-1 appetite suppression. In practice, that means smaller portions and fewer between-meal urges, and both land on the same side of the equation.
One stubborn myth is worth clearing up. The drug does not mainly burn fat or rewrite your metabolism, and it is not chemical liposuction. The FDA label for semaglutide states plainly that it “lowers body weight through decreased calorie intake.”
The weight comes off because intake falls. The fat you lose follows from eating less, not from the drug attacking fat cells directly.
How Big Is the Deficit, in Real Numbers
Put a real number on “you eat less” and it stops being vague. In controlled feeding studies, researchers sit people down at a meal where they can eat as much as they want and weigh what they actually consume, so the drop is measured on a plate, not remembered afterward.
For semaglutide, Friedrichsen 2021 found people ate about 35% less at a single free-choice lunch than on placebo, a difference of roughly 225 calories (about 940 kilojoules) at that one meal. Across a whole day, in Blundell 2017, total intake fell about 24%, around 725 calories (about 3,036 kilojoules) less than placebo, which we unpack in our look at the calorie numbers. For tirzepatide, a six-week trial measured people eating between about 525 and 686 fewer calories a day (roughly 2,205 to 2,880 kilojoules) than placebo, depending on the week.
Those smaller intakes are the engine behind the headline results you may have seen. In the STEP 1 trial, semaglutide produced a 14.9% average drop in body weight at 68 weeks, versus 2.4% on placebo. In SURMOUNT-1, tirzepatide reached up to 22.5% at 72 weeks, against the same 2.4% placebo figure.
| Drug | Trial | Measured intake drop | Weight change |
|---|---|---|---|
| Semaglutide (Wegovy) | Friedrichsen 2021 and Blundell 2017 (intake); STEP 1 (weight) | ~35% less at one meal (Friedrichsen 2021); ~24% less per day (Blundell 2017) | -14.9% at 68 weeks vs -2.4% placebo |
| Tirzepatide (Zepbound) | SURMOUNT-1 | ~525-686 fewer calories per day (~2,205-2,880 kJ) | up to -22.5% at 72 weeks vs -2.4% placebo |
The two molecules go by several names. Semaglutide is sold as Ozempic and Rybelsus in diabetes care and as Wegovy for weight management. Tirzepatide is Mounjaro for diabetes and Zepbound for weight management.
Tirzepatide also carries a second action semaglutide lacks: it activates the GIP receptor as well as the GLP-1 receptor, a dual mechanism that may account for its somewhat larger effect. The trials weren’t run head-to-head for intake, though, so this isn’t a clean contest.
Why the Scale Stalls: The Energy-Out Side Pushes Back
Few things are as discouraging as doing everything right and watching the scale freeze. It rarely means the drug quit. It means the other side of the equation moved.
A deficit isn’t a fixed setting you lock in once. As your body gets smaller, energy out falls too, because a lighter body burns fewer calories just existing. On top of that, the body adds a compensatory cut of its own, spending less than its new size alone would predict.
That extra slowdown is called adaptive thermogenesis. Total energy expenditure can drop roughly 10% to 20% after weight loss. About 60% of that decline comes simply from carrying less body, and the remaining 40% is the compensation beyond being smaller.
So even if you keep eating the same reduced amount, the gap between energy in and energy out narrows, and weight loss slows or stalls. As dietitian Wesley McWhorter puts it, this is “a built-in survival mechanism, not a failure.” Behavior can compound it: around the six-month mark, old eating habits tend to creep back and quietly shrink the deficit further.
None of that means the medication stopped working. It’s still holding your appetite, and your calorie intake, down. The equation has simply re-balanced at a lower weight. Why your body defends a weight range so stubbornly is its own topic.
Where the Medication Fits: Protecting Both Sides
There’s one move you can make this week that the drug can’t make for you: protect your muscle. The medication does one job well, lowering energy in by turning down appetite. It does nothing to defend the energy-out side, and that side is worth defending.
Left unmanaged, roughly 20% to 30% of the weight you lose on a GLP-1 medication can come from lean mass rather than fat. Muscle is active tissue that burns energy, so losing it drags energy out down even further, deepening the stall from the section above.
Two habits push back. Eat enough protein, spread across your meals rather than piled into one, and do resistance training a couple of times a week. Together they have been shown to cut lean-mass loss by 30% to 50% without slowing fat loss. The protein targets and the training details get their own article.
So the medication is one lever on the same energy equation everyone lives under. It makes the calories-in side easier to hold; you look after the calories-out side. Whether a medication is appropriate for you, and at what dose, on-label or off, is a decision to work through with a doctor.
If you want to see how this fits the wider picture of treatment, our overview of GLP-1 weight-loss medication ties these threads together.
FAQ
Do I still have to eat in a calorie deficit on a GLP-1 medication?
Yes, and you already are. The medication creates the deficit for you by lowering your appetite so you eat less than you burn. It isn’t an exception to energy balance; it’s a tool that makes the calories-in side easier to hold down. The same math that governs everyone still applies. The drug just helps you meet it.
Do GLP-1 drugs burn fat directly?
No. Per the FDA label, semaglutide “lowers body weight through decreased calorie intake,” not through a direct fat-burning pathway. The drug acts on appetite centers in the brain and slows stomach emptying, so you eat less. The fat you lose is the result of that sustained calorie deficit, not the drug metabolizing fat cells on its own.
Why did my weight loss plateau even though I’m still on the medication?
Because the energy-out side of the equation fell. As you lose weight, your body burns fewer calories, both from being smaller and from adaptive thermogenesis, an extra compensatory slowdown. Total energy expenditure can drop 10% to 20%, shrinking your deficit even if you eat the same amount. A plateau is expected biology, not the medication failing.
Will the weight come back if I stop?
Often, yes. The drug works only while it’s present, so once you stop, appetite (your energy in) drifts back toward baseline and intake rises. In one analysis, 82% of people regained 25% or more of the weight they had lost within a year of stopping. Regain tends to slow over time and level off below your pre-treatment weight.